The aim of this study was to explore the molecular mechanism through which metformin combined with 2-deoxy-d-glucose (2-DG) decreases the viability of BCPAP thyroid papillary carcinoma cells. BCPAP cells were… Click to show full abstract
The aim of this study was to explore the molecular mechanism through which metformin combined with 2-deoxy-d-glucose (2-DG) decreases the viability of BCPAP thyroid papillary carcinoma cells. BCPAP cells were treated with only metformin, only 2-DG, and both metformin and 2-DG. We used the CCK-8 assay to assess cell viability, dichlorofluorescein staining to detect reactive oxygen species (ROS), and western blot analysis to quantify protein expression. We found that metformin and 2-DG alone decreased cell viability in a time- and dose-dependent manner. The IC50 values of metformin and 2-DG were 5.329 mM and 1.154 mM, respectively. Coadministration of metformin and 2-DG significantly inhibited BCPAP cell proliferation and increased cellular ROS levels and AKT phosphorylation at Ser437. These effects were reversed following the treatment of the cells with N-acetyl-L-cysteine (NAC). Our findings suggest that metformin and 2-DG synergistically suppress BCPAP cell proliferation, potentially via inhibition of the PI3K/AKT signaling pathway by increasing cellular ROS levels.
               
Click one of the above tabs to view related content.